US Government Set To Relaunch Free At-Home COVID-19 Tests Program

Elevated levels of the COVID-19 virus in wastewater samples have prompted the Biden-Harris administration to dust off its free testing program in preparation for the fall and winter. The US Postal Service will begin shipping the testing kits in September.

COVID AT HOME TEST
• Source: Shutterstock

While it’s no longer considered a pandemic, COVID-19 has not gone away.

In fact, the Centers for Disease Control and Prevention reports “very high” levels of the virus in wastewater samples across the US. The CDC says it can detect traces of the virus in sewage samples even if symptoms have not been reported in that community. This data can serve as an early warning of potential spread.

In response to the spike, the Biden-Harris administration says it will relaunch a free testing program which first sent out test kits in January 2022. President Biden first announced the program in December 2021. (Also see "Biden Promises 500 Million COVID-19 Tests As Omicron Threatens To Overwhelm US Health Care System" - Medtech Insight, 21 December, 2021.)

The policy continued sending out additional testing kits throughout 2022 and into 2023.

Now the policy, which allows US households to order up to four free at-home tests through the Department of Health’s Administration for Strategic Preparedness and Response (ASPR) website, will ramp up again toward the end of September with the tests being shipped via US mail.

The new tests, which are designed to detect current variants of the virus, can be taken at home and provide results within 15 to 30 minutes.

“At-home tests are the future of diagnosing disease,” the department says. “Reporting your result — whether negative or positive — helps your nation learn how to use those test results effectively.” — US Department of Health

Additionally, the CDC recommends all Americans older than 6 months get an updated COVID-19 vaccine for the fall and winter to protect against more serious outcomes of infection. However, the government says the tests will work on individuals of any vaccine status.

The government further advises individuals consult the FDA website for expirations dates on all authorized tests before use, as many older COVID-19 tests have expired.

The CDC recommends those testing positive follow the latest guidelines to prevent spreading the disease.

ASPR also notes that the at-home tests are antigen tests, not polymerase chain reaction, or PCR, tests. While antigen tests produce results more quickly than PCRs, they are not as accurate.

Though positive antigen results are accurate and reliable, a single negative result does not necessarily rule out infection. Therefore, the FDA advises people experiencing COVID-19 symptoms see negative results on at least two tests 48 hours apart before considering themselves free of the disease, while people without symptoms should take at least three tests.

A single PCR test, according to the FDA, can confirm an antigen result.

In total, ASPR says the government has sent out more than 900 million tests to households across the country. Health officials have maintained that testing is essential for keeping the virus at bay.

The Department of Health also requests Americans taking the tests to report their results.

“At-home tests are the future of diagnosing disease,” the department says. “Reporting your result — whether negative or positive — helps your nation learn how to use those test results effectively.”

More from Regulation

Update: Italy’s IMQ And Belgium’s SGS Named 15th and 16th IVDR Notified Bodies

 

Ireland’s NSAI reinstated under IVD Regulation designation list

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By 

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

 
• By 

Abbott and J&J reassured investors they will maintain their 2025 profit forecasts. Abbott projects $5.05 to $5.25 per share and plans a new $500m investment in manufacturing and R&D sites. J&J anticipates $400m in tariff-related costs but committed $55bn in US investment over four years.

Notified Bodies Warn Of Hurdles In The Way Of Their AI Designations

 

Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?

More from Policy & Regulation

Makary Proposes Combined Adverse Event Reporting Systems In Megyn Kelly Interview

 

In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.

FDA Issues A Pair Of Early Alerts For Intravascular Catheters

 

The US FDA continues to issue early alerts as part of its communications pilot aimed at improving how the agency manages recalls. This time, the agency is notifying users about two separate intravascular catheters.

Upcoming CMS Meetings Address Tremor-Control Devices, Lab Test Reimbursement

 
• By 

The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.